awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
S10637-012-9815-9
S10637-012-9815-9
http://dx.doi.org/10.1007/S10637-012-9815-9
Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer
P356
Q33400687-E234D257-A973-48D6-9864-6FE76653EC4B
P356
S10637-012-9815-9
http://dx.doi.org/10.1007/S10637-012-9815-9